2008 | May | Apr | Mar | Feb | Jan
2007 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2006 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2005 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2004 | Dec
2008
May
- APP Pharmaceuticals posts rise in Q1 revenues
- CorMatrix granted approval for cardiac implant
- Enterix launches point-of-care cancer screening test
- Atrium granted approval for hernia repair devices
- Jazz secures $75 million in equity financing
- Canadian Court dismisses patent lawsuit against Boston Scientific
- Javelin to raise $27.6 million in direct offering
- Warner Chilcott Q1 revenues rise
- Repros Q1 revenues fall by 15%
- Affymax Q1 net loss rises
- Progenics Q1 loss widens
- FDA approves Novo Nordisk's clot therapy
- ABR-Affinity BioReagents expands distribution partners in Europe
- ProStrakan reports encouraging results from Fortigel study
- Proteome Sciences partners with EU for developing alternatives to animal tests
- Medarex starts Phase II trial of anti-inflammation drug
- Cytochroma names new CFO
- Cardinal Health acquires Enturia
- Affymax and Takeda report positive Phase II data for anemia drug
- Novadaq appoints new CFO
- Novalar obtains FDA approval for OraVerse
- SonoSite names new CFO
- Oragenics reports test marketing of Probiora3 chewable tablets
- Cimex seeks approval for clopidogrel in Germany
- Starpharma reports positive results from VivaGel study
- AmerisourceBergen announces organizational changes
- Orion to stop development of Parkinson's drug candidate
- Sound Surgical signs distribution agreement with GlobalMed
- Oncolytics initiates enrollment for cancer combination therapy trial
- Spectrum sells injectable generic drugs to Sagent
- Enzo Biochem acquires Biomol International
- Hi-Tech Pharmacal signs supply agreement with Warner Chilcott's subsidiary
- Ardea Biosciences names new CFO
- Marshall Edwards extends accrual time for Phase III ovarian cancer trial
- Exactech to raise $20.2 million from sale of common stock
- US Patent Office allows second Vnus patent application
- PolyMedix to start Phase I trial for systemic antibiotic compound
- Celator Pharmaceuticals appoints new CEO
- Barr wins approval for generic contraceptive drug
- SomaLogic and Otsuka enter into research collaboration
- UK court rules against NICE over Alzheimer's guidance
- Inverness Medical acquires Matria Healthcare
- Invitrogen and WARF sign licensing agreement
- Ziopharm granted orphan designation for palifosfamide
- Eusa Pharma acquires Cytogen
- Cytopia and Cancer Therapeutics join hands in drug discovery
- Roche's Actemra found effective in arthritis trial
- Metametrix launches new urinary diagnostic profile
- Alpharma presents safety and efficacy data for pain drug
- Next Pharma's Relora relieves short-term anxiety in healthy women
- US WorldMeds develops dantrolene sodium injection for hyperthermia
- Collegium presents positive clinical data for oral oxycodone formulation
- Uluru to launch Altrazeal wound care dressing
- FDA to boost post marketing safety activities
- OrthoLogic completes dosing in Phase I dermal scarring trial
- Osiris wins approval for Prochymal expanded access program
- Dana-Farber Institute partners with EntreMed in Phase I cancer study
- BiPar to initiate Phase II ovarian cancer trial
- Dor BioPharma acquires option for anthrax vaccine from Harvard University
- LifeCycle Pharma's dyslipidemia drug found effective in Phase II study
- Nektar reports promising results from Phase I study of constipation drug
- Acceleron's bone formation drug found effective in preclinical studies
- Alphatec licenses pedicle screw technology from DePuy and Biedermann
- Cadence completes enrollment in Phase III catheter infection trial
- J&J presents encouraging data from risperidone injection trail
- FDA accepts Lev's complete response submission for Cinryze
- Neuralstem files lawsuit against StemCells
- Aethlon's Hemopurifier found effective in capturing monkeypox virus
- Shire's Vyvanse found effective in Phase III ADHD trial
- Vion initiates Phase I/II cancer trial for Cloretazine with cytarabine
- pSivida to assess efficacy of Medidur FA in macular degeneration trial
- Cardiac Dimensions completes European Amaedus study
- Talecris granted FDA priority review for Gamunex
- Siemens and LabCorp sign diagnostics development agreement
- Globus Medical completes enrollment for cervical disc clinical trial
- Eli Lilly's Strattera wins FDA approval for maintenance of ADHD
- NuVasive to acquire Osteocel business from Osiris
- Cardima raises $5 million in private placement
- Otsuka and Bristol-Myers obtain expanded approval for Abilify
- NationsHealth and CIGNA amend preferred vendor agreement
- ArthroCare's Topaz MicroDebrider found effective against tendon disorders
- Microbix to acquire urokinase from ImaRx
- Astellas's antifungal drug receives European approval
- Enzon to spin off biotechnology business
- Lipid Sciences granted two new patents
- Mylan granted approval to market generic Requip
- Cynosure wins Korean approval to market Accolade
- Acucela files IND application for ocular drug
- COTI granted European patent for leukemia drugs
- Pipex granted notice of allowance for Alzheimer's drug patent
- VioQuest granted patent for dermal drug
- iCo acquires rights to oral antifungal drug
- AMDL signs LOI to acquire GLP
- Cleveland BioLabs completes enrollment for Phase II prostate cancer trial
- WellPoint NextRx and Blue Cross of Idaho extend contract
- XenaCare launches new dietary supplement
- Bayer and Regeneron start second Phase III macular degeneration study
- LFB and GTC to collaborate on recombinant plasma proteins
- Savient reports favorable results from Phase III gout study
- Genzyme presents encouraging results from Phase II Gaucher disease study
- AstraZeneca files sNDA for Seroquel XR
- Advanced BioHealing and Regenesis sign co-promotion agreement
- Shire's Intuniv reduces ADHD symptoms in pivotal trial
- Quest PharmaTech signs agreement with Peking Marvel to sell Bionex
- CardioTech granted approval for second graft size for CardioPass trial
- Wyeth starts Phase II arthritis trial
- Amneal wins FDA approval for three generic drugs
- Shire's Daytrana found effective against ADHD symptoms
- Taisho initiates Phase I trial for psychiatric disorders
- Pall and VWR renew supply agreement
- Nektar obtains patent for pulmonary targeted antibiotics
- ACT Biotech acquires oncology portfolio licenses from Bayer Healthcare
- Forest's Lexapro improves depression symptoms in adolescents
- Champions Biotechnology and ImClone join hands for cancer drugs evaluation
- Opko Health acquires Vidus Ocular
- Menarini submits regulatory filing for Factive in Europe
- Array BioPharma's pain drug meets Phase II study endpoints
- Nucryst appoints new CFO
- Amnis and Gene Company sign marketing agreement
- Roxane launches acarbose tablets
- Spectrum receives $20 million cash payment from Par Pharmaceutical
- Peak's tissue dissection tool found effective in preclinical studies
- Health Discovery signs LoI with DCL to develop cancer test
- NicOx reports encouraging results from Phase IIa glaucoma trial
- Novartis's meningitis vaccine found effective in Phase III trial
- Dalton Pharma signs licensing agreement with Thermo Fisher Scientific
- Catalyst selects new drug candidate for hemophilia program
- Clarient partners with JVHL to offer cancer assays
- SDI signs supply agreement with University of North Carolina
- Poniard completes enrollment of Phase II colorectal cancer trial
- FDA accepts Osteologix's IND application for osteoporosis drug
- MacroGenics names new CFO and chief commercial officer
- Orexigen completes enrollment in Phase III study of obesity drug
- Vascular Insights wins clearance to market infusion catheter
- Dilon granted CE Mark for imaging system
- NovaDel to raise $4 million in financing
- Stanford University to study Pathwork's diagnostic test
- Pluristem granted approval to conduct arterial disease trials
- REGiMMUNE raises $8 million in series B financing
- Fougera granted approval to market generic scalp solution
- Affitech reports milestone achievement in antibody discovery partnership
- Regulus licenses intellectual property from Stanford University
- Warnex signs financing agreement with Desjardins Group
- Alseres signs agreement with BioAxone to amend Cethrin license
- DiaKine and Kinexum to develop new therapy for diabetes treatment
- BMP Sunstone wins clearance for bladder drug study in China
- Prana discovers new drug candidates for Parkinson's research
- Eigen granted clearance for prostate imaging device
- Stiefel acquires ABR Invent and ABR Development
- GT and KMOT to expand cancer detection technology
- Apoptos raises $28 million in series A funding
- EU launches major R&D initiative
- UK drug firms protest against new pricing deal
- UK's R&D in decline, survey finds
- Galapagos and Allergan collaborate in drug discovery
- AstraZeneca files sNDA for Seroquel XR
- DiscoveRx and Caliper Life Sciences announce collaboration
- Indevus reports positive Phase III results for Supprelin LA
- Applied DNA Sciences and Smiths Detection sign MoU
- Contura reports efficacy data from Aquamid study
- Targacept to receive milestone payment from GlaxoSmithKline
- HeartWare granted conditional approval for cardiac device
- QRxPharma presents promising Phase III results for pain therapy
- Volcano to participate in AstraZeneca's Saturn trial
- Roxro wins award for Phase III intranasal pain drug
- NanoViricides's anti-HIV drug candidates found effective in animal studies
- Curis's partner Genentech initiates Phase II colorectal cancer trial
- iClin launches new cancer therapy in Sweden
- Senetek reports positive results from rosacea study
- Xennex licenses GeneCards to Japan Patent Office
- Minerva announces breakthrough in cancer therapy
- Gore granted approval to initiate patent foramen ovale stroke study
- SenoRx granted clearance to modify Contura's product label
- DiaMedica completes enrollment in Phase II diabetes trial
- Can-Fite completes Phase I trial of hepatic drug
- ParagonDx granted clearance for warfarin sensitivity test
- BioElectronics obtains major orders from Italian distributor
- Roxane wins FDA approval for ropinirole hydrochloride tablets
- Bayer Schering granted approval to market oral contraceptive in Europe
- Eisai appoints new president for commercial operations unit
- Spectral and Toray expand collaboration to market diagnostic assay
- Leukemia & Lymphoma Society and MannKind announce collaboration
- Amylin starts Phase IIb obesity trial
- Competitive Technologies submits FDA application for pain management device
- Merck Serono's Raptiva found effective in long-term psoriasis study
- Merck to downsize US sales force
- Mologen to start Phase I study of cancer drug
- GE Healthcare signs diagnostic agreement with Merck
- Minrad to raise $40 million in private placement
- N30 Pharma completes Phase I asthma trial
- Advantage Medical obtains FDA approval for VantageCath
- Cardiva Medical completes $15.5 million equity financing
- Bovie Medical gets CE Mark for laparoscopic line
- Epix begins Phase IIb Alzheimer's program
- Lumenis to implement changes in ophthalmic business unit
- Ipsen's Adenuric obtains European marketing authorization
- Canadian regulatory authority accepts Basilea's alitretinoin application
- Critical Outcome Technologies amalgamates with DDP Therapeutics
- Cell Therapeutics gets favorable opinion to replace brand name
- Bristol-Myers to sell ConvaTec
- McKesson signs settlement with US Drug Enforcement Administration
- Roche exercises option to develop Memory's neurological drug
- Mpathy raises equity and strengthens board of directors
- MedImmune's motavizumab found effective in Phase III RSV trial
- St Jude Medical and Microsoft to enhance access to health records
- Evotec completes acquisition of Renovis
- FDA advisory committee recommends Lev's Cinryze
- Protez begins Phase II study for injectable antibiotic
- Emergent BioSolutions acquires anthrax vaccine and technology
- AstraZeneca files marketing application for lung cancer drug
- Bristol-Myers Squibb to sell Erbitux in Canada
- FDA launches major hiring initiative
- Sepracor and Arrow sign licensing agreement for respiratory product
- Scolr Pharma signs lease buyout agreement
- Nymox reports encouraging results from long term BPH study
- Bovie Medical acquires technology and patents from Boston Scientific
- Molecular Insight initiates Phase IIa Azedra trial in neuroblastoma patients
- DxTech and Nicholas Piramal forge diagnostics alliance
- NeuroMetrix reports executive management change
- AngioScore granted FDA approval for AngioSculpt catheter
- Eusa Pharma divests antibody research business
- Phosphagenics reports positive results of lidocaine drug delivery trial
- HDC reports positive results for prostate cancer test
- Pfizer awards cGMP contract to QSV Biologics
- BD granted CE mark for VRE detection test
- Osteotech and BioHorizons sign distribution agreement
- IVT patents DepoVax vaccine delivery system
- Watson announces approval of new drug delivery system
- CBP granted approval for production of Cryoprecipitate
- Qiagen and BioHelix sign licensing agreement
- 3M and IDRI collaborate in vaccine research
- Summit presents encouraging results from muscular dystrophy study
- Entelos joins hands with biology consortium in diabetic drug discovery
- TorreyPines licenses intellectual property from Johns Hopkins University
- AmpliMed starts Phase II pancreatic cancer trial
- Syneron launches LipoLite device
- APP Pharma announces key management changes
- Merck extends enrollment deadline for Vioxx settlement
- ZymoGenetics presents positive results from Recothrom Thrombin study
- Astute Medical raises $6.2 million in series A financing
- Bio-Bridge signs purchase agreement with Xinheng Baide Biotechnology
- Oncothyreon files new drug application for oncology drug
- Critical Therapeutics to merge with Cornerstone BioPharma
- Angiotech wins FDA approval for smaller Quill SRS PDO
- Shengtai appoints new CFO
- Gilead starts Phase IV study for Letairis
- Sepracor to acquire Oryx Pharma
- Proteolix initiates Phase II cancer trial
- Innocoll initiates dosing in Phase II diabetic foot infection trial
- Biolase names new CFO
- Alexza completes enrollment in Phase IIa panic disorder trial
- Ista reports positive results from Phase III study of conjunctivitis drug
- Apogee files patent for intradermal vaccine technology
- Beckman Coulter acquires rights to Siemens's HCV
- CoNCERT secures $37 million in series C funding
- Protox and FDA collaborate in cancer research
- Transgenomic and NCI partner in mitochondrial genome study
- FDA approves GSK's COPD drug
2008 | May | Apr | Mar | Feb | Jan
2007 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2006 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2005 | Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan
2004 | Dec
back to top